echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > MiR-155 inhibitors treat T-cell lymphoma and are designated by the FDA for orphan drugs.

    MiR-155 inhibitors treat T-cell lymphoma and are designated by the FDA for orphan drugs.

    • Last Update: 2020-07-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The U.S. Food and Drug Administration (FDA) has awarded it the title of cobomarsen orphan drug for the treatment of T-cell lymphoma, the !---- biopharmaceutical company MiRagen Therapeutics announced.Cobomarsen, a miR-155 inhibitor developed by miRagen, is currently being developed in two clinical studies to treat different types of T-cell lymphoma, including Phase 2 clinical trials for skin T-cell lymphoma (CTCL) and Phase 1 clinical trials for adult T-cell leukemia/lymphoma (ATLL).found abnormally high levels of miR-155 in a variety of blood cancer cells. William S,, President and CEO of miRagen, said, "This is an important milestone in the development of cobomarsen, and we believe that cobomarsen has the potential to be used to treat other cancer patients with elevated miR-155." T-cell lymphoma (e.g. ATLL and CTCL) accounts for less than 15% of non-Hodgkin's lymphoma in the United States. there are many types of T-cell lymphoma in, but they are rare.the overexpression of microRNA-155 is associated with prognosis of multiple T-cell lymphomas and other blood cancers..
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.